



Cadila Healthcare Limited

Registered Office : Zydus Tower , Satellite Cross Roads, Ahmedabad - 380015.
Tel. No. (+91-79) 686 8100 Fax No. : (+91-79) 686 2365/66 Website : www.zyduscadila.com
Audited Financial Results for the Quarter ended March 31, 2007.

CONSOLIDATED					Sr.No.	Particulars	COMPANY				
Rupees in Millions							Rupees in Millions				
For the Nine Months period ended on Dec. 31, 2006	Quarter ended March 31,		Year ended March 31,				For the Nine Months period ended on Dec. 31, 2006	Quarter ended March 31,		Year ended March 31,	
	2007	2006	2007	2006		2007	2006	2007	2006		
14272	4475	3501	18747	15078	1	Sales & Income from operations :					
628	264	137	892	625	A	Gross Sales	11561	3453	2904	15014	13082
13644	4211	3364	17855	14453	B	Less : Excise Duty	625	252	136	877	623
287	146	96	433	392	C	Net Sales	10936	3201	2768	14137	12459
13931	4357	3460	18288	14845	D	Other Income from Operations	336	146	85	482	377
249	15	(9)	264	36	E	Total sales and other income from operations	11272	3347	2853	14619	12836
14180	4372	3451	18552	14881	2	Other Income	321	201	50	522	379
					3	Total Income	11593	3548	2903	15141	13215
(524)	(393)	68	(917)	(99)	4	Expenditure :					
5374	1915	1329	7289	5787	A	Increase / Decrease [-] in Stock in Trade	(402)	(324)	134	(726)	(53)
1511	599	441	2110	1804	B	Consumption of Materials	4425	1550	1126	5975	5142
4760	1525	966	6285	4476	C	Staff Cost	1257	476	373	1733	1529
11121	3646	2804	14767	11968	D	Other Expenditure	3755	1242	767	4997	3777
3059	726	647	3785	2913	E	Total Expenditure	9035	2944	2400	11979	10395
169	65	51	234	194	5	Profit before Interest , Depreciation & Tax	2558	604	503	3162	2820
2	(13)	(15)	(11)	57	6 A	Interest & Financial Charges	136	51	41	187	148
171	52	36	223	251	B	Exchange Rate Fluctuations on Foreign Currency Loans	2	(13)	(15)	(11)	57
2888	674	611	3562	2662	C	Total Financial cost	138	38	26	176	205
623	200	194	823	779	7	Profit before Depreciation & Tax	2420	566	477	2986	2615
2265	474	417	2739	1883	8	Depreciation & Amortisation	498	169	163	667	616
0	0	26	0	115	9	Profit before Tax & Exceptional Items	1922	397	314	2319	1999
2265	474	391	2739	1768	10	Less : Exceptional Items	0	0	25	0	111
201	43	28	244	131	11	Profit before tax	1922	397	289	2319	1888
50	(13)	26	37	87	12	Provision for Taxation :					
23	20	5	43	15	A	Current Tax	177	23	27	200	130
0	0	10	0	10	B	Deferred Tax	50	(20)	25	30	85
274	50	69	324	243	C	Fringe Benefit Tax	23	19	5	42	15
1991	424	322	2415	1525	D	Prior Year Tax Adjustments	0	0	9	0	9
(42)	(35)	(16)	(77)	(1)	E	Total provision for taxation	250	22	66	272	239
1949	389	306	2338	1524	13	Profit after tax	1672	375	223	2047	1649
628	628	314	628	314	14	Adjustments on consolidation	0	0	0	0	0
15.52	3.10	2.64	18.62	13.05	15	Net Profit	1672	375	223	2047	1649
15.52	3.10	2.44	18.62	12.13	16	Paid up Equity Share Capital [Face Value Rs. 5 /-]	628	628	314	628	314
					17	Reserves excluding Revaluation Reserve				8195	7049
					18	E P S [Rs.] [For the period - not Annualised]:					
					a	Before extra-ordinary items	13.31	2.99	1.97	16.30	14.01
					b	After extra-ordinary items	13.31	2.99	1.78	16.30	13.13
					19	Aggregate of Non-promoter Shareholding :					
						- Number of Equity Shares	35150458	35150458	17575229	35150458	17575229
						- Percentage of Shareholding	27.98%	27.98%	27.98%	27.98%	27.98%

Notes :

- [1] The above audited results were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on April 26, 2007.
- [2] In Consolidated Accounts, the accounts of foreign subsidiaries / a Joint Venture Company are audited upto December 31, 2006 / February 28, 2007 and subject to limited review by their auditors for the balance period upto March 31, 2007.
- [3] The Board of Directors have recommended a dividend of Rs. 4 [@ 80 %] per equity share on the increased capital of 125,613,708 equity shares of Rs. 5/- each for the financial year ended March 31, 2007.
- [4] During the quarter, USFDA has approved four more ANDAs filed by the Company.
- [5] [A] The Company has made investments in Shares of the following Group Companies during the quarter :

Name of the Concern	Rs. In Millions	
Zydus International Pvt. Ltd., [Wholly owned subsidiary]	45	[Equity Share Application Money]
Zydus Mayne Oncology Pvt. Ltd. [Joint venture]	75	[Preference Share Application Money]
Zydus BSV Pharma Pvt. Ltd. [Joint Venture]	10	
- [B] The company has subscribed Rs. 267 millions to the capital of M/s. Zydus Healthcare, a partnership firm in which the Company is a partner with 96 % share.
- [6] During April 2007, the Company has acquired :
 - [A] 97.5 % stake in Liva Healthcare Ltd., an Indian Pharma company with a derma focused product portfolio.
 - [B] 100 % stake in Nippon Universal Pharmaceuticals Ltd., a privately held company, headquartered at Tokyo, Japan.
- [7] The status of investor complaints :
Pending at the beginning of the quarter - Nil, received and disposed off during the quarter - 26, pending at the end of the quarter - Nil.
- [8] The Company has one segment of activity viz. " Pharmaceuticals ".

By Order of the Board,
For Cadila Healthcare Limited,

Pankaj R.Patel
Chairman & Managing Director

Ahmedabad, April 26, 2007.